Vancomycin Heteroresistance Is Associated with Reduced Mortality in ST239 Methicillin-Resistant Staphylococcus aureus Blood Stream Infections
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vancomycin Heteroresistance Is Associated with Reduced Mortality in ST239 Methicillin-Resistant Staphylococcus aureus Blood Stream Infections
Authors
Keywords
-
Journal
PLoS One
Volume 6, Issue 6, Pages e21217
Publisher
Public Library of Science (PLoS)
Online
2011-06-22
DOI
10.1371/journal.pone.0021217
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vancomycin: We Can't Get There From Here
- (2011) N. Patel et al. CLINICAL INFECTIOUS DISEASES
- Performance of Various Testing Methodologies for Detection of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus in Bloodstream Isolates
- (2011) S. J. van Hal et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Systematic Review and Meta-Analysis of the Significance of Heterogeneous Vancomycin-IntermediateStaphylococcus aureusIsolates
- (2010) Sebastiaan J. van Hal et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications
- (2010) B. P. Howden et al. CLINICAL MICROBIOLOGY REVIEWS
- Prospective Comparison of the Clinical Impacts of Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Susceptible MRSA
- (2009) K. C. Horne et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Staphylococcus aureusBloodstream Infections: Definitions and Treatment
- (2009) G. Ralph Corey CLINICAL INFECTIOUS DISEASES
- Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics
- (2009) Kyra Chua et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Vancomycin MIC plus Heteroresistance and Outcome of Methicillin-Resistant Staphylococcus aureus Bacteremia: Trends over 11 Years
- (2009) A. C. Musta et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Heterogeneous Vancomycin‐Intermediate Susceptibility Phenotype in Bloodstream Methicillin‐ResistantStaphylococcus aureusIsolates from an International Cohort of Patients with Infective Endocarditis: Prevalence, Genotype, and Clinical Significance
- (2009) In‐Gyu Bae et al. JOURNAL OF INFECTIOUS DISEASES
- Reduced Susceptibility to Vancomycin Influences Pathogenicity inStaphylococcus aureusInfection
- (2009) Anton Y. Peleg et al. JOURNAL OF INFECTIOUS DISEASES
- Clinical Features of Heteroresistant Vancomycin-IntermediateStaphylococcus aureusBacteremia versus Those of Methicillin-ResistantS. aureusBacteremia
- (2009) Yasmin Maor et al. JOURNAL OF INFECTIOUS DISEASES
- CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting
- (2008) Teresa C. Horan et al. AMERICAN JOURNAL OF INFECTION CONTROL
- Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia
- (2008) Benjamin P Howden et al. BMC MICROBIOLOGY
- Characterization of Vancomycin-Heteroresistant Staphylococcus aureus from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007)
- (2008) M. J. Rybak et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Influence of Vancomycin Minimum Inhibitory Concentration on the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
- (2007) A. Soriano et al. CLINICAL INFECTIOUS DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More